key: cord-0711190-zizzar4d
authors: Nurnaningsih; Danudibroto, Gladys Indika; Rusmawatiningtyas, Desy; Kumara, Intan Fatah; Makrufardi, Firdian; Widowati, Titis
title: Acute appendicitis in pediatric patients with Coronavirus Disease 2019 (COVID-19): A case series from a developing country's tertiary hospital
date: 2022-01-26
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2022.103315
sha: 90932ef47aeb517f37c04f950f6b5cec75065e40
doc_id: 711190
cord_uid: zizzar4d

INTRODUCTION: and importance: A common gastrointestinal presentation of both COVID-19 and multisystem inflammatory syndrome in children (MIS-C) is acute abdominal pain, which sometimes mimics appendicitis. Literature describing children with COVID-19 infection and concurrent acute appendicitis is growing, and understanding these patients’ clinical picture is necessary for their proper treatment. CASE PRESENTATION: We present a case series of six healthy children before they developed classic symptoms of appendicitis. At the same time, they were also found to have confirmed COVID-19. All patients had fever and right lower abdominal pain. Four of six children having Alvarado score above seven had surgical treatment, while the others only received systemic antibiotic and antiviral medication. Surgical results of two patients revealed perforated appendicitis. No mortality occurred among them. CLINICAL DISCUSSION: There is increasing recognition of gastrointestinal involvement in patients with COVID-19 and MIS-C. There are several postulates to explain appendicitis in COVID-19. First, inflammatory response is exaggerated in SARS-CoV-2 infected patients. Second, obstruction of the appendiceal lumen is caused by mesenteric adenopathy, which in turn, is caused by COVID-19 infection, not fecalith. Third, hyperinflammatory response in MIS-C triggers inflammation in appendix. CONCLUSION: Clinicians must recognize that abdominal pain with fever could be the presenting symptoms of COVID-19 with MIS-C. MIS-C, which has severe presentations with gastrointestinal manifestations and high mortality rate, should be considered as a differential diagnosis for a patient with appendicitis-like symptoms and a positive SARS-CoV-2 infection.

On December 2020, the outbreak of SARS-CoV-2 infection began in Wuhan, China and 28 spread rapidly all over the world. Currently, several studies postulated that COVID-19 in children 29 appears to be milder in clinical manifestations and the pediatric patients have a lower proportion 30 of symptomatic infection than adults [1] . Children infected with the novel Coronavirus 2019 31 (COVID-19) may present with a myriad of symptoms, including fever, cough, anosmia, 32 nausea/vomiting, diarrhea, and more [2] . 

There were 392 pediatric patients admitted to a tertiary hospital with suspected COVID-45 19, with 159 of them being tested positive for COVID-19 using SARS COV-2 PCR during 46 COVID-19 pandemic. The study was located in one of the main university-based referral hospitals 47 in Indonesia. We receive pediatric patients from primary and secondary hospitals in Yogyakarta 48

and Central Java region. Among them, six cases of acute appendicitis were reported among nine 49 referral cases of COVID-19 with appendicitis suspicion (Table 1 ). Patients were 3 to 15 years old, 50 with four of them being male. All patients presented primary symptoms of both right lower 51 abdominal pain and fever, while four patients had vomiting, and only one patient had diarrhea. All 52 patients were previously healthy children, with two of them being obese. Initial assessment at 53 admission showed two patients were in shock and were obese, which posed comorbidities, while 54 the others were in a stable condition. Three patients were admitted to intensive care due to MIS-55

Hemoglobin levels were found normal, while levels of leucocyte, neutrophil, CRP, 57 procalcitonin were elevated in all patients. All patients had tested positive for SARS-CoV-2, but 58 none of them developed respiratory symptoms, and three of them had MIS-C. One of the three 59 patients with MIS-C had increased levels of both aspartate and alanine transaminase. Positive 60 culture was found in two patients; one result was from peritoneal fluid (Escherichia coli), and the 61 other was from feces (Klebsiella pneumoniae). All patients had sterile blood cultures. Two 62 patients, who showed normal chest X-ray results, were either asymptomatic or had a mild degree 63 of COVID-19 infection. The others had COVID-19 bilateral pneumonia with moderate to severe 64 degree of COVID-19 infection. 65

Four of the six patients with Alvarado score of 7-11 had operative treatment, and score of 4 and 6 underwent conservative treatment with antibiotics and frequent reassessment. 68

From the four operative cases, surgery revealed perforated appendicitis in two patients. In the 69 patients of conservative treatment, abdominal pain disappeared in three and seven days after the 70 start of antibiotic administration. COVID-19's specific medication was not indicated for either 71 asymptomatic or mild degree of COVID-19 infection, while one was for both moderate and severe 72 degree of COVID-19 infection. One patient had renal impairment due to MIS-C and required four 73 times hemodialyses during hospitalization. Length of stay of the patients was 5 to 16 days. The 74

shortest hospitalization was found in asymptomatic COVID-19 infection, while the longest 75 hospitalization was found in the male patient with obesity risk, in shock, and with MIS-C. 76

Fortunately, all patients have recovered and been discharged. gastrointestinal symptoms were found to be 70% [11] . This could overlap with signs and symptoms 102 of acute appendicitis. In a previous study, it has been reported that 11.8% of patients with MIS-C 103 have symptoms mimicking those of appendicitis [12] . Three of our patients met the MIS-C criteria, 104 with two of them being admitted both in shock and in a state of being obese. Obesity is a high risk 105 factor in MIS-C since there is accumulation of inflammatory cells in adipose tissue, and fat tissue- 

Epidemiological and clinical features of pediatric COVID-19

Clinical features of pediatric patients with 179 coronavirus disease (COVID-19)

Overcoming COVID-19 Investigators

Inflammatory Syndrome in Children: initial therapy and outcomes

Multi-System of clinical presentation, hypothetical pathogenesis, and proposed management

Guideline: Updating Consensus Preferred Reporting Of CasESeries 200 in Surgery (PROCESS) Guidelines

Clinical characteristics of coronavirus 203 disease (COVID-19) patients with gastrointestinal symptoms: a report of 164 cases

Acute appendicitis in four children with SARS-CoV-207 2 infection

A case of COVID-19 mimicking acute appendicitis in multi-209 system inflammatory syndrome

Multisystem inflammatory 219 syndrome in children (MISC): a systematic review

Pediatric COVID-19 and appendicitis: a gut reaction to SARS-CoV-2? Pediatr 223

Obesity and COVID-19: ACE 2, the missing tile

Hyperinflammatory shock in children during COVID-19 pandemic

Acute appendicitis: efficient diagnosis and management

Antibiotic Therapy vs appendectomy for treatment of uncomplicated acute appendicitis

The APPAC Randomized Clinical Trial

Midwest Pediatric Surgery Consortium

Association of nonoperative management using antibiotic therapy vs laparoscopic 245 appendectomy with treatment success and disability days in children with uncomplicated 246 appendicitis

Mortality in children with positive SARS

CoV-2 polymerase chain reaction test: Lessons learned from a tertiary referral hospital in

Concurrent COVID-19 255 infection in children with acute appendicitis: A report of three cases. Radiol Case Rep

Prevalence 259 of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 260 2019: A systematic review and meta-analysis

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.No potential conflict of interest relevant to this article was reported Please state any sources of funding for your research All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.The authors declare that this study had no funding source.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement.The informed consent form was declared that patient data or samples will be used for educational or research purposes. Our institutional review board also do not provide an ethical approval in the form of case report.J o u r n a l P r e -p r o o f Consent Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions.Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.Written informed consent was obtained from the patient's parents for publication of this case report and accompanying images. A copy of the written consent forms is available for review by the Editor-in-Chief of this journal on request.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors. J o u r n a l P r e -p r o o f

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.researchregistry7479

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish Nurnaningsih J o u r n a l P r e -p r o o f